Candidate microRNA biomarkers in human epithelial ovarian cancer: Systematic review profiling studies and experimental validation

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Chen, Ying ^a,b   Zhang, Lei ^a,b   Hao, Quan ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

Biomarker; MicroRNA; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 100; MICRORNA 125A; MICRORNA 125B; MICRORNA 126; MICRORNA 127; MICRORNA 138; MICRORNA 141; MICRORNA 16; MICRORNA 182; MICRORNA 199A; MICRORNA 200B; MICRORNA 200C; MICRORNA 221; MICRORNA 224; MICRORNA 29C; MICRORNA 335; MICRORNA 494; PROTEIN LET 7A; PROTEIN LET 7B; PROTEIN LET 7C; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CHROMOSOMAL LOCALIZATION; DOWN REGULATION; EPITHELIUM CELL; GENE EXPRESSION PROFILING; HUMAN; OVARY CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SYSTEMATIC REVIEW; UPREGULATION;

EID: 84883083982     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-86     Document Type: Review

References (26)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Coticchia CM, Yang J, Moses MA. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw 2008, 6:795-802. 3381792, 18926090.
3. Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Obermair A. Differentiating Stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecol Oncol 2013, 129:467-71. 10.1016/j.ygyno.2013.03.001, 23500084.
4. Yang N, Coukos G, Zhang L. MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer 2008, 122:963-8.
5. Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. N Engl J Med 2008, 359:2720-2. 10.1056/NEJMe0808667, 19092157.
6. Hede K. Small RNAs are raising big expectations. J Natl Cancer Inst 2009, 101:840-1. 10.1093/jnci/djp172, 19509361.
7. Kim TH, Kim YK, Kwon Y, Heo JH, Kang H, Kim G, An HJ. Deregulation of miR-519a, 153, and 485-5p and its clinicopathological relevance in ovarian epithelial tumours. Histopathology 2010, 57:734-43. 10.1111/j.1365-2559.2010.03686.x, 21083603.
8. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Butzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008, 105:7004-9. 10.1073/pnas.0801615105, 2383982, 18458333.
9. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW, Kim S. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 2008, 14:2690-5. 10.1158/1078-0432.CCR-07-1731, 18451233.
10. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Menard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res 2007, 67:8699-707. 10.1158/0008-5472.CAN-07-1936, 17875710.
11. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih I, Zhang Y, Wood WR, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008, 3:e2436. 10.1371/journal.pone.0002436, 2410296, 18560586.
12. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008, 68:425-33. 10.1158/0008-5472.CAN-07-2488, 18199536.
13. Wyman SK, Parkin RK, Mitchell PS, Fritz BR, O'Briant K, Godwin AK, Urban N, Drescher CW, Knudsen BS, Tewari M. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One 2009, 4:e5311. 10.1371/journal.pone.0005311, 2668797, 19390579.
14. Chao A, Lin CY, Lee YS, Tsai CL, Wei PC, Hsueh S, Wu TI, Tsai CN, Wang CJ, Chao AS, Wang TH, Lai CH. Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene 2012, 31:764-75. 10.1038/onc.2011.269, 21725366.
15. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 2009, 112:55-9. 10.1016/j.ygyno.2008.08.036, 18954897.
16. Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Nerini IF, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections. Lancet Oncol 2011, 12:273-85. 10.1016/S1470-2045(11)70012-2, 21345725.
17. Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 2012, 27:1238-44. 3583406, 22246341.
18. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006, 24:5043-51. 10.1200/JCO.2006.06.7330, 17075124.
19. Chan SK, Griffith OL, Tai IT, Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008, 17:543-52. 10.1158/1055-9965.EPI-07-2615, 18349271.
20. Ma Y, Zhang P, Yang J, Liu Z, Yang Z, Qin H. Candidate microRNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 2012, 130:2077-87. 10.1002/ijc.26232, 21671476.
21. Guan P, Yin Z, Li X, Wu W, Zhou B. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 2012, 31:54. 10.1186/1756-9966-31-54, 3502083, 22672859.
22. Kim SW, Kim JW, Kim YT, Kim JH, Kim S, Yoon BS, Nam EJ, Kim HY. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer 2007, 46:1-9. 10.1002/gcc.20384, 17044060.
23. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006, 130:2113-29. 10.1053/j.gastro.2006.02.057, 16762633.
24. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010, 24:447-63. 10.1210/me.2009-0295, 2817607, 20081105.
25. Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009, 15:5404-13. 10.1158/1078-0432.CCR-09-0365, 2743856, 19690197.
26. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, Sun N, Xu X, Shao K, He J. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol 2013, 30:411.